Imbalance between angiogenic and anti-angiogenic factors in sera from patients with large-vessel vasculitis.


Journal

Clinical and experimental rheumatology
ISSN: 0392-856X
Titre abrégé: Clin Exp Rheumatol
Pays: Italy
ID NLM: 8308521

Informations de publication

Date de publication:
Historique:
received: 27 12 2018
accepted: 01 07 2019
pubmed: 2 10 2019
medline: 10 9 2020
entrez: 2 10 2019
Statut: ppublish

Résumé

To investigate serum levels of a panel of angiogenic inducers (VEGF, FGF-2, Angiopoietin 1, -2, soluble VCAM-1) and inhibitors (angiostatin, endostatin, pentraxin-3) in patients with giant cell arteritis (GCA) and Takayasu's arteritis (TAK), in order to gain further insights into the molecular mechanisms driving angiogenesis dysregulation in large-vessel vasculitis (LVV). Sera were obtained from 33 TAK patients and 14 GCA patients and from two groups of age-matched normal controls (NC). Disease activity was assessed using 18F-FDG PET/CT and clinical indices including NIH/Kerr criteria and ITAS. Angiogenic and anti-angiogenic factor serum levels were evaluated using commercial ELISA kits. Pentraxin 3 (PTX3) serum levels were evaluated by non-commercial ELISA, as already described. Among the angiogenic factors, only VEGF serum levels were significantly higher in TAK patients compared to NC. No difference was found between angiogenic factor levels in GCA patients compared to those detected in NC. Anti-angiogenic factor (Angiostatin, Endostatin, PTX3) serum levels were significantly higher in both GCA and TAK patients compared to NC. Significant associations were observed between VEGF and PTX3 levels and disease activity evaluated using PET scan and clinical indices. Cluster analysis based on PET scan scores in TAK patients showed significant ordered differences in VEGF and angiostatin serum levels. Indeed, we noted a progressive increase of VEGF and angiostatin from NC to the cluster including patients with the highest and more diffuse scan positivity. Our overall results demonstrate a circulating molecular profile characterised by a prevailing expression of anti-angiogenic soluble factors.

Identifiants

pubmed: 31573481
pii: 13798

Substances chimiques

ANGPT1 protein, human 0
ANGPT2 protein, human 0
Angiogenic Proteins 0
Angiopoietin-1 0
Angiopoietin-2 0
Angiostatic Proteins 0
Endostatins 0
Serum Amyloid P-Component 0
VEGFA protein, human 0
Vascular Cell Adhesion Molecule-1 0
Vascular Endothelial Growth Factor A 0
Fibroblast Growth Factor 2 103107-01-3
PTX3 protein 148591-49-5
Angiostatins 86090-08-6
C-Reactive Protein 9007-41-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

23-30

Auteurs

Lia Pulsatelli (L)

Laboratory of Immunorheumatology and Tissue Regeneration, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy. lia.pulsatelli@ior.it.

Luigi Boiardi (L)

Division of Rheumatology, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Italy.

Elisa Assirelli (E)

Laboratory of Immunorheumatology and Tissue Regeneration, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.

Giulia Pazzola (G)

Division of Rheumatology, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Italy.

Francesco Muratore (F)

Division of Rheumatology, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Italy.

Olga Addimanda (O)

Medicine and Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, and Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy.

Paolo Dolzani (P)

Laboratory of Immunorheumatology and Tissue Regeneration, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.

Annibale Versari (A)

Nuclear Medicine Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Italy.

Massimiliano Casali (M)

Nuclear Medicine Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Italy.

Barbara Bottazzi (B)

Department of Inflammation and Immunology, Humanitas Clinical and Research Center IRCCS, Milan, Italy.

Luca Magnani (L)

Division of Rheumatology, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Italy.

Elettra Pignotti (E)

Medicine and Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.

Nicolò Pipitone (N)

Division of Rheumatology, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Italy.

Stefania Croci (S)

Clinical Immunology, Allergy and Advanced Biotechnologies Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Italy.

Alberto Mantovani (A)

Department of Inflammation and Immunology, Humanitas Clinical and Research Center IRCCS, Milan; Humanitas University, Milan, Italy, and The William Harvey Research Institute, Queen Mary University of London, UK.

Carlo Salvarani (C)

Division of Rheumatology, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, and University of Modena and Reggio Emilia, Italy.

Riccardo Meliconi (R)

Medicine and Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, and Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH